Literature DB >> 25543098

Vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolated from a patient who never received vancomycin treatment.

Xuhui Zhu1, Cailin Liu2, Sui Gao1, Yanfang Lu1, Zhongju Chen1, Ziyong Sun3.   

Abstract

BACKGROUND: With the abuse of antibiotics, the methicillin-resistant Staphylococcus aureus (MRSA) strain became prevalent. Furthermore, Staphylococcus aureus with a character of vancomycin intermediate-resistance (VISA) has been found globally since the first report in Japan. The main objectives of this study were to report a case of VISA isolated from a Chinese patient who had never undergone Vancomycin treatment, and to determine its molecular character.
METHODS: A total of 9 strains were recovered from a patient during the therapeutic process. Antimicrobial susceptibility testing was performed to determine their antibiotic susceptibility patterns. To detect the VISA strain's molecular epidemiological features, growth and morphological characters, we used multilocus sequence typing, autolysis assay and transmission electric microscope tests. Pulsed-field gel electrophoresis (PFGE) was performed to characterize the heterogeneities of all isolates.
RESULTS: One isolate was found to exhibit vancomycin intermediated-resistant with MIC of 8 μg/ml. It was ST239-T030-agr-1, had thickened cell wall, and displayed a slower growth rate and reduced susceptibility to Triton X-100-induced autolysis than other strains. All 9 strains exhibited the same PFGE pattern.
CONCLUSION: This is the first report of VISA found in central China from a patient who had never received vancomycin treatment.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Molecular typing; Staphylococcus; VISA; Vancomycin intermediated-resistant Staphylococcus aureus

Mesh:

Substances:

Year:  2014        PMID: 25543098     DOI: 10.1016/j.ijid.2014.12.038

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  8 in total

1.  Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.

Authors:  Yong Pil Chong; Ki-Ho Park; Eun Sil Kim; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

2.  The use of vancomycin in the treatment of adult patients with methicillin-resistant Staphylococcus aureus (MRSA) infection: a survey in a tertiary hospital in China.

Authors:  Jing Tang; Jiali Hu; Lei Kang; Zhengjun Deng; Jiaofen Wu; Jiaqian Pan
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Decreased Vancomycin MICs among Methicillin-Resistant Staphylococcus aureus Clinical Isolates at a Chinese Tertiary Hospital over a 12-year Period.

Authors:  Chaohui Lu; Yinjuan Guo; Shanshan Wang; Zhengzheng Wang; Lan Chen; Jinnan Lv; Xiuqin Qi; Zengqiang Chen; Lizhong Han; Xueqing Zhang; Liangxing Wang; Fangyou Yu
Journal:  Front Microbiol       Date:  2016-10-27       Impact factor: 5.640

4.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

5.  Phenotypic and Molecular Characterisation of Staphylococcus Aureus with Reduced Vancomycin Susceptibility Derivated in Vitro.

Authors:  Jia Xu; Long Pang; Xiao Xue Ma; Jian Hu; Yuan Tian; Ya Li Yang; Dan Dan Sun
Journal:  Open Med (Wars)       Date:  2018-10-22

6.  Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.

Authors:  Manuel Kussmann; Matthias Karer; Markus Obermueller; Katy Schmidt; Wolfgang Barousch; Doris Moser; Marion Nehr; Michael Ramharter; Wolfgang Poeppl; Athanasios Makristathis; Stefan Winkler; Florian Thalhammer; Heinz Burgmann; Heimo Lagler
Journal:  Emerg Microbes Infect       Date:  2018-12-05       Impact factor: 7.163

7.  Molecular characterization of vancomycin-resistant Staphylococcus aureus strains isolated from clinical samples: A three year study in Tehran, Iran.

Authors:  Marjan Shekarabi; Bahareh Hajikhani; Alireza Salimi Chirani; Maryam Fazeli; Mehdi Goudarzi
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

8.  In Vitro Activity of Vancomycin, Teicoplanin, Linezolid and Daptomycin Against Methicillin-Resistant Staphylococcus aureus Isolates Collected from Chinese Hospitals in 2018-2020.

Authors:  Yanlei Xu; Bingjie Wang; Huilin Zhao; Xinyi Wang; Lulin Rao; Wenxiu Ai; Jingyi Yu; Yinjuan Guo; Xiaocui Wu; Fangyou Yu; Shuying Chen
Journal:  Infect Drug Resist       Date:  2021-12-16       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.